Research Article

Anemia in Inflammatory Bowel Disease Outpatients: Prevalence, Risk Factors, and Etiology

Carla Valéria de Alvarenga Antunes, Abrahão Elias Hallack Neto, Cristiano Rodrigo de Alvarenga Nascimento, Liliana Andrade Chebli, Ivana Lúcia Damásio Moutinho, Bruno do Valle Pinheiro, Maycon Moura Reboredo, Carla Malaguti, Antonio Carlos Santana Castro, and Júlio Maria Fonseca Chebli

Division of Gastroenterology, Department of Medicine, Inflammatory Bowel Diseases Center, University Hospital of the Federal University of Juiz de Fora, University of Juiz de Fora School of Medicine, Avenida Eugênio do Nascimento s/n, Dom Bosco, 36038-330 Juiz de Fora, MG, Brazil

Correspondence should be addressed to Júlio Maria Fonseca Chebli; chebli@globo.com

Received 2 September 2014; Revised 12 November 2014; Accepted 12 November 2014

Academic Editor: Sachiyo Nomura

Copyright © 2015 Carla Valéria de Alvarenga Antunes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Anemia is common in inflammatory bowel disease (IBD). However, epidemiological studies of nonwestern IBD populations are limited and may be confounded by demographic, socioeconomic, and disease-related influences. This study evaluated the prevalence, risk factors, and etiology of anemia in Brazilian outpatients with IBD.

Methods. In this cross-sectional study, 100 Crohn’s disease (CD) patients and 100 ulcerative colitis (UC) subjects were assessed. Anemia workup included complete blood count, ferritin, transferrin saturation, serum levels of folic acid and vitamin B₁₂, and C-reactive protein (CRP) concentration.

Results. The overall prevalence of anemia in IBD was 21%. There was no significant difference in the prevalence of anemia between CD subjects (24%) and UC (18%). Moderate disease activity (OR: 3.48, 95% CI, 1.95–9.64, \(P=0.002\)) and elevated CRP levels (OR: 1.8, 95% CI, 1.04–3.11, \(P=0.02\)) were independently associated with anemia. The most common etiologies of anemia found in both groups were iron deficiency anemia (IDA; 10% on CD and 6% on UC) followed by the anemia of chronic disease (ACD; 6% for both groups).

Conclusions. In Brazilian IBD outpatients, anemia is a highly concurrent condition. Disease moderate activity as well as increased CRP was strongly associated with comorbid anemia. IDA and/or ACD were the most common etiologies.

1. Introduction

Inflammatory bowel diseases (IBDs) are idiopathic multisystemic disorders that present with periods of relapses and remissions throughout their clinical course [1]. While ulcerative colitis (UC) is characterized by inflammation limited to the colonic mucosa, in Crohn’s disease (CD) transmural inflammation is observed that can affect any part of the gastrointestinal tract [2]. In many patients, these conditions cause substantial personal cost, due to the unpredictable fluctuating symptoms, absenteeism at work, use of high-cost drugs, surgeries, or multidisciplinary care.

The severity of the intestinal manifestations (i.e., diarrhea, abdominal pain, and bleeding) is usually an important guide for management of IBD. Occasionally, however, one or more extraintestinal manifestations can be the predominant clinical feature on patients with IBD. Notably, anemia is one of the most common extraintestinal manifestations (or complications) in IBD [3–5]. In this clinical setting, anemia can contribute to patients’ poor quality of life, particularly because of its negative impact on the feeling of wellbeing, physical performance, mood, cognitive function, and capacity to perform social activities [6, 7]. In addition, comorbid anemia in IBD individuals is a significant predictor of increased risk of hospitalization and even increased patient mortality [8–10]. Of note, anemia may occasionally both anteced the development of intestinal symptoms and be the key signal unmask IBD [3, 6].
The prevalence of anemia in IBD varies widely, with studies reporting a frequency between 8.8% and 74% depending on the assessed patient subpopulation [11, 12]. Etiology of anemia in IBD is multifactorial. Nonetheless, iron deficiency and characteristics of chronic disease are the most prevalent in this clinical setting [11–13].

Periodic screenings for anemia as well as a systematic diagnostic approach are essential steps to the appropriate management of this condition on IBD. However, anemia is both underdiagnosed and undertreated in populations with IBD [14]. Furthermore, different geographic, demographic, socioeconomic, and disease-related characteristics may exist between South American and North American or European populations that may limit the generalization of the findings regarding the epidemiology of anemia on IBD individuals, as the data are mainly derived from North American or European studies.

Therefore, the purpose of the present cross-sectional cohort study was to assess the prevalence, risk factors, and etiology of anemia in a Brazilian population with IBD. We hypothesized that anemia would be a concurrent condition in this patient population and is correlated with inflammatory activity.

2. Methods

2.1. Study Design. We conducted a cross-sectional cohort study of adult outpatients with IBD from an IBD Center at the University Hospital of the Federal University of Juiz de Fora, Brazil, that were enrolled consecutively into this study for evaluation of the anemia between November 2012 and January 2013.

2.2. Participants. Our goal was to recruit 200 IBD patients (100 with CD and 100 with UC), nearly 20% of the IBD cohort followed in our Center.

The diagnosis of CD or UC was confirmed by combinations of clinical, radiologic, endoscopic, and histopathological criteria generally accepted for CD or UC [2]. The inclusion criteria were age ≥18 and < 65 years and a confirmed diagnosis of IBD (CD or UC). Patients were excluded if they were younger than 18 or older than 65 years or presented with a severe IBD requiring hospitalization. Patients were also considered ineligible if they had a previous or current history of malignancies (except cutaneous), prior gastrectomy, systemic infections in the last 3 months, alcohol abusive use (daily alcohol consumption above 40 g), drug addiction, disabling chronic organ failure, or replacement therapy with iron, folic acid, or vitamin B₁₂, in the last six months. Pregnant women or nursing mothers were not selected.

2.3. Measurements and Outcomes

2.3.1. Sociodemographic and Disease-Related Characteristics. On inclusion, the eligibility criteria were assessed and medical history was recorded. Patient’s relevant sociodemographic data included age, gender, current smoking (more than one cigarette daily), and history of alcohol consumption.

The classification and extent of the patients’ IBD were established using the Montreuil classification [15]. CD activity was measured according to Crohn’s disease activity index (CDAI). Scores below 150 indicated remission and higher scores indicated active disease (i.e., mild to moderate disease: CDAI between 150 and 219; moderate to severe disease: CDAI between 220 and 450). For UC patients we used Truelove and Witt’s criteria [16]. Thus, clinical remission was defined by ≤ 2 or 3 stools/day, without the presence of blood and/or pus in the stools, with no systemic symptoms; mild activity: up to 4 stools/day, with or without blood, no systemic involvement, and increased inflammatory markers; moderate activity: >4 stools per day with minimal systemic symptoms and increased inflammatory markers; severe activity: >6 stools per day with blood and evidence of systemic involvement, such as fever, tachycardia, anemia, and erythrocyte sedimentation above 30. In addition, disease duration and IBD-related surgical history were recorded as well.

2.3.2. Evaluation of Anemia. During the inclusion in the study, blood samples (20 mL) for hematological and clinical chemistry were obtained. Anemia workup included complete blood count, ferritin, serum iron, transferrin saturation (TfS), serum levels of folic acid and vitamin B₁₂, a reticulocyte count, erythrocyte sedimentation, and quantitative C-reactive protein (CRP) concentration.

According to the definition of the World Health Organization, the cutoff point for anemia was hemoglobin (Hb) levels below 13 g/dL in males and below 12 g/dL in nonpregnant females [17]. Severe anemia was defined as Hb < 10 g/dL for both genders. CRP was considered as elevated when the CRP levels were >6 mg/L. Patients were classified to have iron deficiency anemia (IDA) if there was a reduction in serum ferritin below 30 μg/L or TfS was ≤16% in the absence of clinical and/or biochemical (i.e., CDAI ≤ 150 and CRP below or equal to upper limit of normality) data suggestive of disease activity; in the presence of inflammation (e.g., CDAI > 150 and/or CRP above upper limit of normality), IDA was diagnosed by a serum ferritin < 100 μg/L and/or TfS < 16% [6].

In the presence of clinical or biochemical evidence of intestinal inflammation, the diagnostic criteria for anemia of chronic disease (ACD) were a serum ferritin > 100 μg/L and TfS < 16% [6, 9]. A combination of IDA and ACD was defined by finding of a serum ferritin level between 30 and 100 μg/L [6, 11]. Anemia due to vitamin B₁₂ deficiency or anemia caused by folic acid deficiency was diagnosed when there were low serum levels of these vitamins in patients with anemia. If an absolute reticulocyte count was above 100,000, anemia was classified as hemolytic.

2.4. Statistical Analysis. The statistical analysis was performed using SPSS 16.0 (SPSS, Chicago, IL, USA). Continuous variables are presented as medians and ranges, and categorical variables are expressed as number and percentage of patients. Descriptive statistics of all relevant variables for the groups were calculated. For data analysis, the patients were divided into two groups (subjects with and without
anemia) according to their Hb levels. Comparisons between groups as well as possible relationships between the presence of anemia with sociodemographic and disease-related data were analyzed using parametric Student’s $t$-tests, nonparametric chi-squared tests, or the Mann-Whitney $U$ test, as appropriate. Univariate and multivariate logistic analysis was performed to identify independent predictors for occurrence of anemia in the whole IBD group. The results are presented as odds risk (OR) and 95% confidence intervals (CI). For comparison, the level of statistical significance was set at $P < 0.05$ and all reported $P$ values are two-tailed.

3. Results

3.1. Baseline Patient Characteristics. A total of 221 adult IBD outpatients were screened for the study. Of them, 18 individuals (8.1%) were not enrolled because they presented with some of the exclusion criteria: severe IBD requiring hospitalization ($n = 4$), colon cancer ($n = 1$), active infectious ($n = 2$), alcohol abusive use ($n = 2$), previous gastrectomy ($n = 1$), end-stage renal disease ($n = 1$), pregnancy ($n = 2$), and recent therapy with iron ($n = 5$). Three patients refused to participate after reading the informed consent. Thus 200 patients (90.5%) of the eligible population (75 males, 125 females, median age: 42 years (range 19–60)) were included. The demographic and clinical characteristics of the IBD cohort at baseline are shown in Table I.

3.2. Assessment of Anemia in Patients with IBD. The overall prevalence of anemia was 21%. The prevalence was similar among patients with CD (24%) and UC subjects (18%; $P = 0.25$) (Table I). No patient presented with severe anemia. There was no correlation between the occurrence of anemia with demographics, IBD location or duration, behavior of CD, and previous surgery for IBD. Conversely, IBD patients with moderate disease activity (CDAI between 220 and 450 for CD or $> 4$ stools per day and increased inflammatory markers for UC) had significantly higher prevalence of anemia (66.7%) than patients in remission (17.8%) or with mildly active CD (18.9%) ($P < 0.001$ for both comparisons). This finding was more notable for UC individuals with moderate disease activity ($P = 0.001$) than the CD patients ($P = 0.024$) presenting moderate activity (Table I). In addition, CRP levels were significantly higher in both diagnostic groups with anemia than those in the population without anemia ($P < 0.001$ for CD and $P = 0.009$ for UC). Interestingly, smokers had a lower prevalence of anemia ($P = 0.047$).

As shown by univariate logistic regression analysis, the risk of anemia was 4-fold higher for moderate disease activity and 2-fold higher for no smoking (Table 2). Increase in CRP by each 1 mg/L increased this risk by 90%. In multivariate model, independent variables associated with anemia were moderate disease activity and CRP. Moderate disease increased 3.5-fold the risk of anemia, whereas each 1 mg/L increase in CRP increased this probability by 80%. However, in multivariate analysis, no smoking was not associated with an increased OR for anemia.

The most common etiologies of anemia found in both patients with CD and UC were IDA (10% in CD and 6% in UC subjects) followed by the ACD (6% in both groups) and $B_12$ vitamin deficiency (5% in both groups). A total of 4% of the IBD cohort presented with concomitant IDA and ACD and only one patient showed folate deficiency associated with IDA (Table 3).

4. Discussion

This study demonstrated the magnitude of anemia in Brazilian patients with IBD. It clearly shows that current anemia was strongly associated with both moderate disease activity and higher CRP levels. To the best of our knowledge, this is the first study to demonstrate that moderate disease activity is a more important risk factor for anemia in UC patients than that in CD individuals. Furthermore, IDA and/or ACD were the most common etiologies of the anemia on the IBD setting.

The prevalence of anemia in our patients with IBD was 21%. This finding is in accordance with an overall prevalence of anemia (24%, 95% CI, 18–31) found on a recent meta-analysis evaluating 2192 IBD patients in European countries [18]. Other studies reported similar prevalence between 17% and 20% [19–21] which differs from the higher prevalence of anemia found in the studies of Bergamisch et al. [13] (65%) and Høivik et al. [4] (48.8% on CD and 20.2% on UC). This probably is due to the fact that our study was conducted in patients who were already under IBD treatment while the latter two studies evaluated patients before starting treatment. In current study, the prevalence of comorbid anemia was similar among patients with CD and UC subjects. Disparately, other studies reported anemia occurring more frequently in patients with CD than that in those with UC [4, 11]. It is possible that selection bias on inclusion in our study (i.e., more patients with UC presented with disease activity than CD patients) can justify this difference.

No patient in the current study had severe anemia. It, however, included only outpatients and individuals with severe IBD requiring hospitalization and higher probability of presenting with severe anemia were excluded. Furthermore, our study population is followed in an IBD center where patients are regularly monitored and treated to the target of tight control of intestinal inflammation. Notoriously, the degree of anemia in IBD patients correlates with underlying disease activity [18, 22]. It is another good reason to opt for expeditious, aggressive restraint of intestinal inflammation.

Similar to the finding in other studies [6, 7, 12, 19, 21], we have revealed that the two most commonly found patterns of anemia in IBD were IDA and that of chronic disease. Although the distinction between IDA and the ACD is important for IBD individuals, both conditions commonly overlap. It is well known that continuous or recurrent intestinal blood loss, reduced iron absorption from the inflamed bowel, and systemic iron sequestration drive a negative iron balance in IBD [1, 3, 11]. Conversely, a main mechanism driving ACD is the interleukins-6 release from the inflamed intestine that can trigger increased hepcidin hepatic synthesis, which potentially decreased duodenal absorption of iron and retained iron within cells of the reticular-endothelial system [23]. In addition, IBD individuals can have difficulty in utilizing iron appropriately because it has low levels of
Table 1: Demographic and clinical characteristics of the inflammatory bowel disease patients with and without anemia.

|                          | Crohn's disease | Ulcerative colitis | Total |
|--------------------------|-----------------|--------------------|-------|
|                          | Anemia          | No anemia          | Anemia| No Anemia | Anemia | No anemia | Total |
| Gender n (%)             |                 |                    |       |
| Female                   | 11 (17.2)       | 53 (82.8)          | 11    | 50 (82)   | 22 (17.6) | 103 (82.4) |
| Male                     | 13 (36.1)       | 23 (63.9)          | 07    | 32 (82.1) | 20 (26.7) | 55 (73.3)  |
| Age, year (median/range) | 38.9 (18–64)    | 42.2 (19–63)       | 41.1  | 45.6 (19–65) | 41.1 (18–64) | 43.9 (19–65) |
| Disease activity* n (%)  |                 |                    |       |
| In remission             | 17 (19.5)       | 70 (80.5)          | 7     | 41 (85.4)  | 24 (17.8) | 111 (82.2) |
| Mild                     | 4 (50)          | 4 (50)             | 6     | 39 (86.7)  | 10 (18.9) | 43 (81.1)  |
| Moderate                 | 3 (60)          | 2 (40)             | 5     | 2 (28.6)   | 8 (66.7)  | 4 (33.3)   |
| CD location n (%)        |                 |                    |       |
| Ileal                    | 8 (34.8)        | 15 (65.2)          |       |           |         |           |
| Colonic                  | 7 (20.6)        | 27 (79.4)          |       |           |         |           |
| Ileocolonic              | 9 (20.9)        | 34 (79.1)          |       |           |         |           |
| UC location n (%)        |                 |                    |       |
| Ulcerative proctitis     |                 |                    | 8     | 45 (84.9)  |         |           |
| Left sided UC            |                 |                    | 2     | 18 (90)    |         |           |
| Extensive UC             |                 |                    | 8     | 19 (70.4)  |         |           |
| Behavior of CD n (%)†    |                 |                    |       |
| B1                       | 8 (21.6)        | 29 (78.4)          |       |           |         |           |
| B2                       | 7 (25)          | 21 (75)            |       |           |         |           |
| B3                       | 9 (25.7)        | 26 (74.3)          |       |           |         |           |
| Disease duration (year)  |                 |                    |       |
| (median/range)           | 6.4 (1.4–12.8)  | 8 (0.8–11.6)       | 7.4   | 7.7 ± 5.2 (1–11) | 6.8 ± 7.0 (1.4–12.8) | 7.8 ± 6.2 (0.8–11.6) |
| Previous surgery n (%)   |                 |                    |       |
| Yes                      | 9 (23.1)        | 30 (76.9)          | 1     | 1 (50)     | 10 (24.4) | 31 (75.6) |
| No                       | 15 (24.6)       | 46 (65.4)          | 17    | 81 (82.7)  | 32 (20.1) | 127 (79.9) |
| Smoking** n (%)          |                 |                    |       |
| Yes                      | 2 (11.1)        | 16 (88.9)          | 1     | 16 (94.1)  | 3 (8.6)  | 32 (91.4)  |
| No                       | 22 (26.8)       | 60 (73.2)          | 17    | 66 (79.5)  | 39 (23.6) | 126 (76.4) |
| CRP*** (mg/L) (median/range) | 12.9 (1–80) | 4.6 (1–45)         | 9.9   | 4.9 (1–30) | 11 (1–80) | 3.5 (1–45) |

CD: Crohn's disease; UC: ulcerative colitis; CRP: C-reactive protein.

* For moderate disease activity there was a statistically significant difference with \( P = 0.024 \) (CD), \( P = 0.001 \) (UC), and \( P < 0.001 \) (for total population).

** For smoking there was a statistically significant difference with \( P = 0.047 \) (for total population).

*** For CRP there was a statistically significant difference with \( P < 0.001 \) (CD) and \( P = 0.009 \) (UC).

† B1: nonstricturing, nonpenetrating; B2: stricturing; B3: penetrating.

erythropoietin for their severity of anemia [22]. Systemic inflammatory cytokines increase (e.g., interleukins-6 and TNF-alpha, among others) has been shown to decrease mRNA expression of erythropoietin [24]. It is interesting to highlight that treatment with antitumor necrosis factor-alpha agents has been shown to improve iron deficiency by improving erythropoiesis, implicating a role for TNF-alpha in development of ACD and/or IDA in IBD patients [13].

A major finding of the present study was the strong correlation between anemia and disease activity in IBD patients. Moderate disease activity was an independent factor that increased 3.5-fold the risk of anemia. In particular, patients with moderate activity have a higher prevalence of anemia than those in remission or presenting with mild activity. This is the first study to show that this finding was more evident for UC subjects with moderate disease activity than the CD patients. It is possible to speculate that UC patients during flares can present with higher bleeding rate than CD patients, which can entail more IDA. This result suggests that, during follow-up of IBD patients, more intensive screening for anemia should be carried out during flare IBD, especially in UC patients with activity disease.

Other previous studies found that IBD patients with active disease status are more likely to have anemia than
Table 2: Univariate and multivariate logistic regression analysis for occurrence of anemia in the whole inflammatory bowel disease group.

|                      | OR     | −95% CI  | +95% CI  | P     |
|----------------------|--------|----------|----------|-------|
| **Univariate logistic regression analysis for anemia risk** |        |          |          |       |
| Gender               | 0.957  | 0.912    | 1.242    | 0.63  |
| Age                  | 1.263  | 0.674    | 3.487    | 0.59  |
| Inactive disease     | 1.438  | 0.497    | 2.764    | 0.75  |
| Mild disease activity| 2.614  | 1.345    | 6.243    | 0.09  |
| Moderate disease activity | 4.101  | 2.503    | 10.542   | <0.001|
| Disease duration     | 0.989  | 0.646    | 1.728    | 0.21  |
| Previous surgery     | 1.345  | 0.587    | 3.843    | 0.57  |
| No smoking           | 1.912  | 1.088    | 4.531    | 0.04  |
| CRP                  | 1.905  | 1.047    | 3.354    | 0.001 |

|                      | OR     | −95% CI  | +95% CI  | P     |
|----------------------|--------|----------|----------|-------|
| **Multivariate logistic regression analysis for anemia risk** |        |          |          |       |
| No smoking           | 0.912  | 0.878    | 2.531    | 0.14  |
| Moderate disease activity | 3.487  | 1.954    | 9.643    | 0.002 |
| CRP                  | 1.803  | 1.048    | 3.113    | 0.02  |

OR: odds risk; CI: confidence intervals; CRP: C-reactive protein.

Table 3: Etiology of the anemia on patients with inflammatory bowel disease.

|                      | ACD (%) | B₁₂ deficiency (%) | IDA (%) | ACD + IDA (%) |
|----------------------|---------|---------------------|---------|---------------|
| Crohn’s disease (n = 100) | 6       | 5                   | 10*     | 3             |
| Ulcerative colitis (n = 100) | 6       | 5                   | 6       | 1             |
| Total (n = 200)           | 12      | 10                  | 16      | 4             |

ACD: anemia of chronic disease; IDA: iron deficiency anemia.
* One Crohn’s disease patient presented with concomitant IDA and folate deficiency.

those being in remission [1, 11, 18]. Indeed, it should be emphasized that more inflammatory activity probably results in more blood loss, increased release of hepcidin, and decreased iron absorption from the intestine. Additionally, our observation that elevated CRP is positively associated with anemia is consistent with that of Høivik et al. [4]. It is worth remembering that CRP is an acute phase protein that represents a nonspecific serum marker of inflammation. Active IBD, especially CD, is associated with a CRP response in 40–80% of patients [25]. Thus, intestinal inflammation plays an integral role in the development of anemia in IBD individuals. Particularly in the setting of active disease and/or an increased CRP level, the suspicion of underlying anemia should be raised, which should be looked for carefully. However, it is important to point that about 18% (Table 1) of the patients with IBD had anemia despite having no active disease. Therefore, regardless of whether the patient has IBD in remission, screening for anemia may be still worthwhile.

Interestingly, in agreement with Høivik et al. [4], we have revealed a negative correlation between smoking and anemia by univariate analysis. It has been shown that smokers can develop secondary polycythaemia caused by exposure to carbon monoxide by smoking [26]. Nonetheless, in our multivariate model smoking was not associated with reduced odds for anemia. Hence, the possible protective role of the cigarette against the development of the anemia in IBD remains open to debate.

Ultimately, we believe that attention about the prevalence, risk factors, and different etiologies of anemia in patients with IBD could allow those personalized, targeted therapies for patients to be correctly adjusted according to the patient’s need, thus potentially offering an opportunity for improvement of health-related quality of life, working ability, and patient satisfaction.

A limitation of the study is the fact that the occurrence of the anemia in IBD should ideally be assessed in a longitudinal rather than a cross-sectional study design. Furthermore, the burden of anemia found in our IBD patients may not completely reflect the true prevalence of anemia in the general IBD population. In the present study, the patients with IBD were at an IBD center of a university hospital, which makes them more likely to be a more ill or troubled group of IBD patients than those who would be seen in a community setting. It is generally accepted that patients with more severe disease are more likely to experience anemia [22]. This might bias the results toward a higher prevalence than those in the IBD population in general. Thus, our results should be interpreted in the appropriate context. Ultimately, future research through longitudinal studies is needed to examine what the impact of the aggressive management of IBD...
on both the incidence and severity of the anemia in IBD patients is.

5. Conclusion

In Brazilian IBD outpatients, anemia is highly concurrent condition, deserving special attention. IDA and ACD are the most common types of anemia in this clinical setting. Our data underline that anemia in IBD is largely correlated with inflammatory activity. So adequate treatment should target both the proper correction of Hb levels and aggressive management of active IBD with close monitoring, which could afford the opportunity for giving a better patient's quality of life. The high prevalence of anemia in IBD patients together with the availability of effective treatment for this condition indicates that it is timely to recommend that periodic screening and appropriate management for anemia should be carried out routinely as part of quality of care improvement for all patients with IBD.

Ethical Approval

The study protocol was defined in accordance with the Declaration of Helsinki and was approved by the Human Use Investigation Committee of our institution. All patients signed a freely informed consent form before being admitted to the study. The confidentiality patient identity and records were maintained.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This study was partly supported by a clinical research fund from the CNpq and FAPEMIG, Brazil.

References

[1] S. Kulnigg and C. Gasche, “Systematic review: managing anemia in Crohn’s disease,” *Alimentary Pharmacology and Therapeutics*, vol. 24, no. 11-12, pp. 1507–1523, 2006.

[2] G. S. de Souza, F. M. Vidigal, L. A. Chebli et al., “Effect of azathioprine or mesalazine therapy on incidence of re-hospitalization in sub-occlusive ileocecal Crohn’s disease patients,” *Medical Science Monitor*, vol. 19, no. 1, pp. 716–722, 2013.

[3] C. Gasche, “Anemia in IBD: the overlooked villain,” *Inflammatory Bowel Diseases*, vol. 6, no. 2, pp. 142–150, 2000.

[4] M. L. Hovik, W. Reinisch, M. Cvanacarova, and B. Moum, “Anemia in inflammatory bowel disease: a population-based 10-year follow-up,” *Alimentary Pharmacology and Therapeutics*, vol. 39, no. 1, pp. 69–76, 2014.

[5] D. Guagnonzo and A. J. Lucendo, “Anemia in inflammatory bowel disease: a neglected issue with relevant effects,” *World Journal of Gastroenterology*, vol. 20, no. 13, pp. 3542–3551, 2014.

[6] C. Gasche, A. Berstad, R. Befrits et al., “Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases,” *Inflammatory Bowel Diseases*, vol. 13, no. 12, pp. 1545–1553, 2007.

[7] C. W. Wells, S. Lewis, J. R. Barton, and S. Corbett, “Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients,” *Inflammatory Bowel Diseases*, vol. 12, no. 2, pp. 123–130, 2006.

[8] J. P. Gisbert, F. Bermejo, R. Pajares et al., “Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement,” *Inflammatory Bowel Diseases*, vol. 15, no. 10, pp. 1485–1491, 2009.

[9] K. Liu and A. J. Kaffes, “Iron deficiency anaemia: a review of diagnosis, investigation and management,” *European Journal of Gastroenterology and Hepatology*, vol. 24, no. 2, pp. 109–116, 2012.

[10] R. Befrits, O. Wikman, L. Blomquist et al., “Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life,” *Scandinavian Journal of Gastroenterology*, vol. 48, no. 9, pp. 1027–1032, 2013.

[11] F. Gomollón and J. P. Gisbert, “Anemia and inflammatory bowel diseases,” *World Journal of Gastroenterology*, vol. 15, no. 37, pp. 4659–4666, 2009.

[12] A. Wilson, E. Reyes, and J. Ofman, “Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature,” *The American Journal of Medicine*, vol. 116, supplement 1, no. 7, pp. 44–49, 2004.

[13] G. Bergamaschi, A. di Sabatino, R. Albertini et al., “Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-α treatment,” *Haematologica*, vol. 95, no. 2, pp. 199–205, 2010.

[14] C. Ott and J. Scholmerich, “Extraintestinal manifestations and complications in IBD,” *Nature Reviews Gastroenterology & Hepatology*, vol. 10, no. 10, pp. 585–593, 2013.

[15] M. S. Silverberg, J. Satasangi, T. Ahmad et al., “Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology,” *The Canadian Journal of Gastroenterology*, vol. 19, pp. 5A–36A, 2005.

[16] S. C. Truelove and L. J. Witts, “Cortisone in ulcerative colitis; final report on a therapeutic trial,” *British Medical Journal*, vol. 2, no. 4947, pp. 1041–1048, 1955.

[17] World Health Organization, “Iron deficiency anaemia assessment, prevention and control. A guide for programme managers,” Report WHO/NHP/01.3, World Health Organization, Geneva, Switzerland, 2011.

[18] N. Filmann, J. Rey, S. Schneeweiss et al., “Prevalence of anemia in inflammatory bowel diseases in European countries: a systematic review and individual patient data meta-analysis,” *Inflammatory Bowel Diseases*, vol. 20, no. 5, pp. 936–945, 2014.

[19] P. Bager, R. Befrits, O. Wikman et al., “The prevalence of anemia and iron deficiency in IBD outpatients in Scandinavia,” *Scandinavian Journal of Gastroenterology*, vol. 46, no. 3, pp. 304–309, 2011.

[20] J. P. Gisbert and F. Gomollón, “Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease,” *The American Journal of Gastroenterology*, vol. 103, no. 5, pp. 1299–1307, 2008.

[21] R. A. Alves, S. J. Miszputen, and M. S. Figueiredo, “Anemia in inflammatory bowel disease: prevalence, differential diagnosis and association with clinical and laboratory variables,” *Sao Paulo Medical Journal*, vol. 132, no. 3, pp. 140–146, 2014.
[22] S. Schreiber, S. Howaldt, M. Schnoor et al., “Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease,” *The New England Journal of Medicine*, vol. 334, no. 10, pp. 619–623, 1996.

[23] E. Nemeth, S. Rivera, V. Gabayan et al., “IL-6 mediates hypoferrremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin,” *The Journal of Clinical Investigation*, vol. 113, no. 9, pp. 1271–1276, 2004.

[24] W. Jelkmann, “Proinflammatory cytokines lowering erythropoietin production,” *Journal of Interferon & Cytokine Research*, vol. 18, no. 8, pp. 555–559, 1998.

[25] J. D. Lewis, “The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease,” *Gastroenterology*, vol. 140, no. 6, pp. 1817–1826, 2011.

[26] J. A. Leifert, “Anaemia and cigarette smoking,” *International Journal of Laboratory Hematology*, vol. 30, no. 3, pp. 177–184, 2008.